In the article "Disabling CCR5 Could Be Key to a C
Post# of 145796
![](/assets/46931549/no_avatar_available_thumb.jpg)
Their citing of the white paper "Deviations from Hardy Weinberg Equilibrium at CCR5-Δ32 in Large Sequencing Data Sets?" is a bit off since the contributing data is not trustworthy and states that at the top of the paper.
https://www.biorxiv.org/content/10.1101/768390v2
But then we come to leronlimab. Leronlimab establishes only a partial blockade of the CCR5 receptor and still allows immune system function. That the developers of leronlimab chose this particular molecular structure was quite fortuitous.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)